46results about How to "Small dose of immunization" patented technology

The invention aims at providing a new castle disease and H9 subtype bird flu bivalent vaccine. The new castle disease and H9 subtype bird flu bivalent vaccine contains antigens and adjuvant. The antigens are inactivated H9 subtype bird flu viruses and new castle disease viruses. The H9 subtype bird flu viruses are QDY strains, and the preservation number of the H9 subtype bird flu viruses is CCTCC v201517. The QDY strains of the H9 subtype bird flu viruses and a Lasota strain of the new castle disease viruses are inoculated to chick embryos respectively, and then virus liquid is collected; the virus liquid and the oil adjuvant are mixed and emulsified into the vaccine after the virus liquid is inactivated through a formaldehyde solution. The new castle disease and bird flu bivalent inactivated vaccine is good in immunogenicity, antibody production is fast after immunity, the produced antibody titer is high, the produced antibody holding time is long, the retention period is long, the immunizing dose is small, the selected adjuvant is easy to inject, and two kinds of diseases can be prevented through one-time injection. The vaccine has the advantages of being efficient and good in safety.

The invention provides a porcine epidemic diarrhea virus inactivated vaccine. The porcine epidemic diarrhea virus inactivated vaccine contains the inactivated porcine epidemic diarrhea virus and an adjuvant, wherein the adjuvant is prepared from the following components in percentage by weight: 5% of squalane, 1% of oleic acid, 1% of Tween 80, 92% of 0.005M sodium citrate buffer solution, and 1% of beta-glucan, the porcine epidemic diarrhea virus is prepared by inactivating the porcine epidemic diarrhea virus strain PEDV-KB2013-4, is assigned with the microbial accession number of CGMCC No.12663, has the classification name of Porcine Epidemic Diarrhea Virus (PEDV), and is preserved in the China General Microbiological Culture Collection Center (CGMCC) on Aug 23, 2016, and the preservation address is the Institute of Microbiology of Chinese Academy of Sciences located in 3, Courtyard 1, West Beichen Road, Chaoyang District, Beijing.

The invention relates to a preparing method of porcine pseudorabies virus subunit vaccine composition. The preparing method includes the steps that 1, a gB protein fragment gene and a gD protein gene are cloned and amplified respectively; 2, the amplified gB protein fragment gene and the amplified gD protein gene are used for constructing plasmid of tandem expression gB protein and gD protein; 3, gB+gD recombinant protein is expressed through the obtained plasmid of tandem expression gB protein and gD protein and purified, adjuvant is added, and emulsification is carried out. The preparing method is simple, porcine pseudorabies virus gB and gD protein can be prepared in quantity, shorter time is spent, the expression amount is large, the production cost is greatly reduced, which is beneficial for large-scale production. The virus subunit vaccine containing the prepared gB and gD protein is good in immune effect and small in immune amount and capable of effectively preventing diseases related to the porcine pseudorabies virus and related infectious diseases caused by the porcine pseudorabies virus.

The invention provides a combined concentrated and inactivated vaccine of Newcastle disease and H9 subtype avian influenza, which contains an inactivated Newcastle disease virus LaSota strain, an inactivated H9 subtype avian influenza virus HL strain and an adjuvant. The invention further provides a preparation method of the combined concentrated and inactivated vaccine. According to the combinedconcentrated and inactivated vaccine provided by the invention, the immunizing dose of the vaccine is reduced to one third of a traditional vaccine, namely, the immunizing dose of the vaccine is reduced from 0.3 ml to 0.1 ml per chick which is 1-5 weeks old, by means of increasing the antigen content in unit volume of the vaccine so that the stress reaction of vaccine immunity to an organism is reduced. Furthermore, the vaccine provided by the invention is applied to chicken with a small age in days so that the application range of the vaccine is widened. In addition, the immunity effect of the vaccine provided by the invention is not reduced on the premise of reducing the dose of the vaccine. Therefore, the combined vaccine of the Newcastle disease and the avian influenza, provided by the invention, has the advantages of small dose of the vaccine, better immune effect, lower cost and longer immune protection period.

The invention discloses a koi herpesvirus ORF25 nucleic acid vaccine, which has good immunogenicity. According to the koi herpesvirus ORF25 nucleic acid vaccine, ORF25 gene is cloned to an eukaryotic expression vector pIRES-neo to obtain recombined plasmid. The koi herpesvirus ORF25 nucleic acid vaccine has effective prevention effect to koi herpes.

The invention provides a nucleotide sequence, a fiber2 protein, an expression method of the fiber2 protein and a duck type 3 adenovirus and duck tembusu virus bivalent inactivated vaccine. The nucleotide sequence is used for coding the duck type 3 adenovirus antigenic fragment fiber2 protein, the nucleotide sequence is shown as SEQ NO:2, and the amino acid sequence of the duck type 3 adenovirus antigenic fragment fiber2 protein is shown as SEQ NO:3; a fiber2 protein gene segment and a pET-32a vector segment are connected through T4DNA ligase to obtain a pET-32a-fiber2 recombinant expression vector, then the pET-32a-fiber2 recombinant expression vector is converted into an expression strain E.coli BL-21 (DE3) competent cell for cultivation, and the fiber2 protein and the duck type 3 adenovirus and duck tembusu virus bivalent inactivated vaccine are obtained from culture; used antigens of the bivalent inactivated vaccine comprise the duck type 3 adenovirus antigenic fragment fiber2 protein and inactivated duck tembusu viruses; and the volume ratio of the two antigens in the bivalent inactivated vaccine is 1:1, the duck tembusu viruses are duck tembusu virus DF2 strains, and the preservation number of the duck tembusu virus DF2 strain is CCTCC NO: V201635.

The invention relates to an optimized porcine circovivus type 2 recombinant adenovirus construction method. The construction of recombinant adenovirus is completed by cloning Human cytomegalovirus first intron (Intron A) and woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) into an adenovirus shuttle vector. The construction method provided by the invention has the advantages that a Cap expression quantity is improved, so that adenovirus usage dose and adenovirus protein autoimmune response can be relieved and the preparation efficiency of the porcine circovivus type 2 recombinant adenovirus can be improved.

The invention provides a method for preparing a quadruple inactivated vaccine by adopting VP2 protein of a bursal disease virus variant FJ19 (with the preservation number of CGMCC NO: 19381), and a corresponding vaccine. Antigens of the vaccine are a newcastle disease La Sota virus strain, an avian influenza TL18 strain (with the preservation number of CGMCC NO: 19382), a VP2 protein of a bursal disease virus variant FJ19 and an I group 8b type avian adenovirus Hexon protein. The quadruple inactivated vaccine disclosed by the invention is high in VP2 protein and Hexon protein content, high inimmunogenicity and low in formaldehyde and endotoxin content, has a relatively good protection effect on the currently popular variant bursal disease virus FJ19 and the group I 8b type avian adenovirus, is good in safety performance and definite in immune effect, can resist infection of Newcastle disease virus, avian influenza virus, variant bursal disease virus and group I 8b type avian adenovirus to clinical chicken flocks at the same time, is small in immune dose and long in duration, can reach the immune duration of 5 months under the condition of only 0.3 mL once, and at least provides aprotection rate of 70% for the chicken flocks.

The invention provides bivalent inactivated vaccine for porcine parvovirus and porcine epizootic diarrhea. The bivalent inactivated vaccine comprises antigen and a vaccine adjuvant, wherein the antigen is a porcine epidemic diarrhea virus with the preservation number being CGMCC No. 8503 and porcine parvovirus VP2 protein with the preservation number being CCTCC M 2016098, wherein the porcine parvovirus VP2 protein is expressed by an X33-VP2 strain; the strain was preserved in China Center for Type Culture Collection on 9, March, 2016. The bivalent inactivated vaccine for porcine parvovirus and porcine epizootic diarrhea is good in immunogenicity, an immunized antibody is generated quickly, the generated antibody is high in titer and long in holding time and retention period, the immunizing dose is small, the selected vaccine adjuvant is easy to inject, and the two types of diseases can be prevented and treated through single injection; if immune injection is conducted before mating, piglets born by a pregnant sow can obtain good passive immunity, the piglets can generate high immunity and can resist to attack of powerful viruses, and the survival rate of the piglets is raised.

The invention discloses a veterinary bovine ephemeral fever inactivated vaccine and a large-scale production method thereof, and belongs to the technical field of vaccine production. The method provided by the invention comprises the steps of performing cell culture by utilizing a suspension culture process, performing virus suspension culture, performing virus antigen solution clarification, performing concentration and purification, performing inactivation and performing emulsification vaccine preparation, and the method can realize mass proliferation of the bovine ephemeral fever virus, improves the content and yield of the virus antigen, and has a high automation degree; The synergistic effect of all the steps can jointly improve the quality and stability of the vaccine, and the technical problems that the yield of the bovine ephemeral fever virus produced by cell culture through a traditional spinner bottle or microcarrier process is low, the process is tedious, the difference between virus antigen batches is large, the vaccine efficacy is low, the vaccine validity period is short and the like are solved.

The invention provides an all-round nuclease Benzonase ELISA (Enzyme-Linked Immuno Sorbent Assay) detection kit. The Benzonase ELISA detection kit comprises: a rabbit-derived Benzonase polyclonal antibody; a rabbit-derived Benzonase polyclonal antibody marked by biotin; an HRP labeled by avidin; a standard substance Benzonase; a color developing solution, a stop solution, a confining solution and a washing solution. The lower detection limit of the detection kit is 24 pg/ml, the quantitative detection range is 0.047-3 ng/ml, Benzonase of different manufacturers can be detected, and an imported Benzonase detection kit can be replaced. Meanwhile, methodological system evaluation is carried out on a constructed ELISA detection system, and the kit is good in specificity and high in detection accuracy.

The invention provides a preparation method of an SS anti-idiotype monoclonal antibody, and belongs to the technical field of bioengineering and vaccine preparation. The method disclosed by the invention comprises the following steps: (1) coupling SS with a macromolecular protein carrier to obtain an SS immunogen complex; (2) carrying out primary immunization on animals with the SS immunogen complex to obtain an SS antibody; (3) carrying out secondary immunization on the animals which are the same or different from the animals in the step (2) with the SS antibody to obtain an SS anti-idiotype monoclonal antibody. The SS anti-idiotypic monoclonal antibody can be prepared by using the method disclosed by the invention. The SS anti-idiotypic monoclonal antibody prepared by the invention can be used as the vaccine to immunize the animals, so that the animals can produce the SS antibodies to immunize and neutralize SS in vivo, thereby promoting the release of growth hormones to promote the growth of the animals.

The invention discloses a nucleic acid vaccine for kio hepesvirus. The nucleic acid vaccine has high immunogenicity. The nucleic acid vaccine for the kio hepesvirus is a recombinant plasmid which is obtained by cloning an ORF81 gene into a eucaryon expression vector pIRES-neo. The nucleic acid vaccine for the kio hepesvirus has an effective preventative effect on a kio herpesvirus disease.

The invention relates to a staphylococcus aureus TRAP recombinant protein antigen of a targeted dendritic cell DEC205 receptor. The nucleotide sequence of the staphylococcus aureus TRAP recombinant protein antigen is shown as SEQ ID No. 1. The invention further relates to a staphylococcus aureus TRAP recombinant protein antigen of the targeted presentation cell FC receptor, and the nucleotide sequence of the staphylococcus aureus TRAP recombinant protein antigen is shown as SEQ ID No.2. The TRAP protein and the receptor peptide fragment of the targeted antigen presenting cell are recombined together, so that the humoral immune response level of a mouse body is enhanced, the cellular immune response level of the mouse is obviously enhanced, and the problem of intracellular infection parasitism of staphylococcus aureus is solved; according to the method, the immunometering of the vaccine is remarkably reduced, the utilization efficiency of the vaccine is improved, and the immune protection rate of the vaccine is increased to 90% and is remarkably higher than that of untargeted TRAP protein, so that the immune cost is reduced, and the popularization of the vaccine for preventing the cow mastitis is accelerated.